Physician profile
Sudha Karupaiah
NPI 1316984800
$1,666.68
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $513 · 2021: $738 · 2022: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $418.97 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $308.73 | 2019-2021 | |
| Glaxosmithkline, LLC. | $244.88 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $136.01 | 2019-2022 | |
| Abbvie INC. | $133.49 | 2021-2022 | |
| Eisai INC. | $97.91 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $96.24 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $48.54 | 2021 | |
| Mylan Specialty L.P. | $37.08 | 2019 | |
| Philips North America LLC | $29.09 | 2019 | |
| Resmed Corp | $25.13 | 2019 | |
| Abbott Laboratories | $22.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudha Karupaiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.